CMB — Cambium Bio Share Price
0.000.00%
Last trade - 00:00- AU$3.85m
- AU$3.78m
- AU$0.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.29 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -131.07% | ||
| Return on Equity | -983.9% | ||
| Operating Margin | -693.8% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1.66 | 7.07 | n/a | n/a | 0.13 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Its technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Elate Ocular is formulated from the processing of base human platelets sourced not from patients, but generally healthier younger eligible donors at U.S. blood collection centers. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It also manufactures and sells stem cell growth supplements, such as UltraGRO Advanced, UltraGRO Pure (xeno-free), and UltraGRO Pure GI (xeno-free, gamma irradiated).
Directors
- Barry Sechos NEC
- Karolis Rosickas CEO
- John Bird CFO
- Graham Vesey CSO
- Charlotte Morgan OTH
- Duncan Thomson OTH
- Hang Ling Leung SEC
- Leo Yao Lee NED
- John Chiplin NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 14th, 2007
- Public Since
- September 19th, 2013
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 13,280,389
- Address
- 2 Paddington Street, Paddington, PYMBLE, 2021
- Web
- https://www.cambium.bio/
- Phone
- +61 294998010
- Auditors
- Stantons International Audit and Consulting PTY Ltd
Upcoming Events for CMB
Similar to CMB
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Cambium Bio share price?
As of Today at 19:44 UTC, shares in Cambium Bio are trading at AU$0.29. This share price information is delayed by 15 minutes.
How has the Cambium Bio share price performed this year?
Shares in Cambium Bio last closed at AU$0.29 and the price had moved by -67.78% over the past 365 days. In terms of relative price strength the Cambium Bio share price has underperformed the ASX All Ordinaries Index by -69.11% over the past year.
What are the analyst and broker recommendations for Cambium Bio?
There is no consensus recommendation for this security.
Find out moreWhat is the Cambium Bio dividend yield?
Cambium Bio does not currently pay a dividend.
Does Cambium Bio pay a dividend?
Cambium Bio does not currently pay a dividend.
When does Cambium Bio next pay dividends?
Cambium Bio does not currently pay a dividend.
How do I buy Cambium Bio shares?
To buy shares in Cambium Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cambium Bio?
As of the previous close price of AU$0.29, shares in Cambium Bio had a market capitalisation of AU$3.85m.
Where are Cambium Bio shares listed?
Here are the trading details for Cambium Bio:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CMB
What kind of share is Cambium Bio?
Based on an overall assessment of its quality, value and momentum Cambium Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cambium Bio share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Cambium Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cambium Bio. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -33.9%.
As of the last closing price of AU$0.29, shares in Cambium Bio were trading -39.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cambium Bio PE Ratio?
The Cambium Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cambium Bio?
Cambium Bio's management team is headed by:
- Barry Sechos - NEC
- Karolis Rosickas - CEO
- John Bird - CFO
- Graham Vesey - CSO
- Charlotte Morgan - OTH
- Duncan Thomson - OTH
- Hang Ling Leung - SEC
- Leo Yao Lee - NED
- John Chiplin - NID